Stock Analysis on Net

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

$24.99

Economic Value Added (EVA)

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Economic Profit

Regeneron Pharmaceuticals Inc., economic profit calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Net operating profit after taxes (NOPAT)1
Cost of capital2
Invested capital3
 
Economic profit4

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 NOPAT. See details »

2 Cost of capital. See details »

3 Invested capital. See details »

4 2025 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= × =


The financial performance, as measured by economic profit, demonstrates fluctuations over the five-year period. Net operating profit after taxes (NOPAT) experienced a significant decrease from 2021 to 2022, followed by relative stabilization and a slight increase in subsequent years. Invested capital generally increased throughout the period, while the cost of capital remained relatively stable. Consequently, economic profit mirrored the trend in NOPAT, exhibiting a substantial decline initially, then a period of recovery, but not returning to the levels seen in 2021.

Net Operating Profit After Taxes (NOPAT)
NOPAT decreased considerably from US$7,819,887 thousand in 2021 to US$3,547,649 thousand in 2022, representing a decline of over 50%. From 2022 to 2023, NOPAT continued to decrease, albeit at a slower rate, reaching US$2,823,336 thousand. A modest recovery was observed in 2024, with NOPAT increasing to US$3,374,924 thousand, followed by a slight decrease to US$3,147,470 thousand in 2025. This suggests potential challenges in maintaining profitability, followed by some stabilization and limited growth.
Cost of Capital
The cost of capital remained consistently high throughout the period, ranging between 9.48% and 9.62%. A slight increase was observed from 9.48% in 2021 to 9.59% in 2022, followed by a peak of 9.62% in 2023. The cost of capital then decreased marginally to 9.57% in 2024 and 9.56% in 2025. The relative stability indicates consistent financing costs, which likely influenced the economic profit calculations.
Invested Capital
Invested capital increased from US$10,786,500 thousand in 2021 to US$12,287,700 thousand in 2022, representing a substantial increase. It decreased slightly in 2023 to US$11,998,500 thousand, before increasing again to US$12,653,600 thousand in 2024 and further to US$13,198,700 thousand in 2025. This upward trend suggests continued investment in the business, potentially to support future growth, despite fluctuations in profitability.
Economic Profit
Economic profit followed a similar trajectory to NOPAT. It decreased dramatically from US$6,797,787 thousand in 2021 to US$2,368,646 thousand in 2022. Further decline occurred in 2023, reaching US$1,669,000 thousand. A recovery was seen in 2024, with economic profit rising to US$2,164,573 thousand, but it decreased slightly again in 2025 to US$1,885,582 thousand. The magnitude of economic profit decreased significantly, indicating a reduced ability to generate returns exceeding the cost of capital.

Overall, the period was characterized by a substantial initial decline in economic profit, followed by a partial recovery that did not reach previous levels. The consistent cost of capital and increasing invested capital suggest that maintaining profitability remains a key challenge.


Net Operating Profit after Taxes (NOPAT)

Regeneron Pharmaceuticals Inc., NOPAT calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Net income
Deferred income tax expense (benefit)1
Increase (decrease) in deferred revenue2
Increase (decrease) in equity equivalents3
Interest expense
Interest expense, operating lease liability4
Adjusted interest expense
Tax benefit of interest expense5
Adjusted interest expense, after taxes6
Interest income
Investment income, before taxes
Tax expense (benefit) of investment income7
Investment income, after taxes8
Net operating profit after taxes (NOPAT)

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 Elimination of deferred tax expense. See details »

2 Addition of increase (decrease) in deferred revenue.

3 Addition of increase (decrease) in equity equivalents to net income.

4 2025 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =

5 2025 Calculation
Tax benefit of interest expense = Adjusted interest expense × Statutory income tax rate
= × 21.00% =

6 Addition of after taxes interest expense to net income.

7 2025 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= × 21.00% =

8 Elimination of after taxes investment income.


The financial performance, as indicated by Net Income and Net Operating Profit After Taxes (NOPAT), demonstrates considerable fluctuation over the five-year period. A significant decline in both metrics is observed between 2021 and 2023, followed by a partial recovery in subsequent years.

NOPAT Trend
NOPAT experienced a substantial decrease from US$7,819,887 thousand in 2021 to US$2,823,336 thousand in 2023, representing a decline of approximately 64%. This suggests a weakening in core operational profitability. A subsequent increase to US$3,374,924 thousand in 2024 indicates some recovery, but NOPAT decreased again in 2025 to US$3,147,470 thousand, suggesting the recovery may not be sustained.
Relationship between Net Income and NOPAT
While both Net Income and NOPAT follow a similar pattern of decline and partial recovery, NOPAT consistently represents a larger value than Net Income. This difference could be attributed to factors not reflected in net income, such as non-operating expenses or gains, or differences in accounting treatment. The gap between the two metrics appears relatively stable throughout the period.

The observed volatility in NOPAT warrants further investigation to determine the underlying drivers. Potential areas of inquiry include changes in revenue, cost of goods sold, operating expenses, and tax rates. The decrease in 2025, following the 2024 increase, suggests potential challenges in maintaining operational efficiency or market position.

Overall Performance
The period under review demonstrates a period of instability. While the company shows some ability to recover from the low point in 2023, the performance in 2025 indicates that the recovery may be limited. Continued monitoring of NOPAT and its contributing factors is recommended.

Cash Operating Taxes

Regeneron Pharmaceuticals Inc., cash operating taxes calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Income tax expense
Less: Deferred income tax expense (benefit)
Add: Tax savings from interest expense
Less: Tax imposed on investment income
Cash operating taxes

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


The relationship between income tax expense and cash operating taxes demonstrates notable fluctuations over the five-year period. Cash operating taxes generally exceed income tax expense, suggesting timing differences between reported accounting income and actual cash outflows for taxes.

Overall Trend - Cash Operating Taxes
Cash operating taxes exhibit a decreasing trend from 2021 to 2023, followed by a slight increase in 2024 and a more substantial rise in 2025. The value decreased from US$1,400,760 thousand in 2021 to US$995,682 thousand in 2023, representing a 28.9% decline. A modest increase to US$989,515 thousand occurred in 2024, before a significant jump to US$1,372,884 thousand in 2025.
Overall Trend - Income Tax Expense
Income tax expense shows a significant decrease from 2021 to 2022, followed by continued declines through 2023, a slight increase in 2024, and a further increase in 2025. The value fell from US$1,250,500 thousand in 2021 to US$245,700 thousand in 2023, a decrease of 80.3%. An increase to US$367,300 thousand was observed in 2024, and a further increase to US$725,800 thousand in 2025.
Relationship Between Tax Items
The difference between cash operating taxes and income tax expense varied considerably. In 2021, cash operating taxes exceeded income tax expense by US$150,260 thousand. This difference narrowed in 2022 to US$725,998 thousand. By 2023, cash operating taxes exceeded income tax expense by US$750,000 thousand. The difference decreased to US$622,115 thousand in 2024, and then increased to US$647,084 thousand in 2025. This suggests that deferred tax assets or liabilities are playing a significant role in the company’s tax position.

The substantial fluctuations in both income tax expense and cash operating taxes warrant further investigation to understand the underlying drivers, such as changes in tax laws, the utilization of tax credits, or alterations in the company’s accounting practices related to deferred taxes. The increasing trend in both measures in 2025 suggests a potential increase in future tax liabilities.


Invested Capital

Regeneron Pharmaceuticals Inc., invested capital calculation (financing approach)

US$ in thousands

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Finance lease liabilities, current portion
Long-term debt
Finance lease liabilities, excluding current portion
Operating lease liability1
Total reported debt & leases
Stockholders’ equity
Net deferred tax (assets) liabilities2
Deferred revenue3
Equity equivalents4
Accumulated other comprehensive (income) loss, net of tax5
Adjusted stockholders’ equity
Construction in progress6
Marketable securities7
Invested capital

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 Addition of capitalized operating leases.

2 Elimination of deferred taxes from assets and liabilities. See details »

3 Addition of deferred revenue.

4 Addition of equity equivalents to stockholders’ equity.

5 Removal of accumulated other comprehensive income.

6 Subtraction of construction in progress.

7 Subtraction of marketable securities.


The invested capital of the organization demonstrates a generally increasing trend over the five-year period, although with some fluctuation. Total reported debt & leases and stockholders’ equity both contribute to this figure, and their individual movements influence the overall invested capital.

Invested Capital Trend
Invested capital increased from US$10,786,500 thousand in 2021 to US$12,287,700 thousand in 2022, representing a substantial rise. A decrease was then observed in 2023, with invested capital falling to US$11,998,500 thousand. Subsequent years show renewed growth, reaching US$12,653,600 thousand in 2024 and US$13,198,700 thousand in 2025. This suggests periods of capital investment followed by potential adjustments or reallocations.
Debt & Leases
Total reported debt & leases exhibits a consistent, albeit moderate, upward trend throughout the period. Starting at US$2,767,900 thousand in 2021, it increases to US$2,972,700 thousand in 2025. The increases are relatively steady year-over-year, indicating a consistent reliance on debt financing.
Stockholders’ Equity
Stockholders’ equity demonstrates a strong and consistent upward trend. It increased significantly from US$18,768,800 thousand in 2021 to US$31,256,900 thousand in 2025. This growth suggests successful earnings retention and/or new equity issuance, contributing significantly to the overall increase in invested capital.
Relationship between Components
While both debt & leases and stockholders’ equity contribute to invested capital, stockholders’ equity represents the larger portion and drives the majority of the overall trend. The relatively smaller increases in debt & leases are overshadowed by the substantial growth in equity. The dip in invested capital in 2023 appears to be influenced by a combination of factors, including a slight decrease in equity growth and the impact of debt levels.

In summary, the organization’s invested capital has generally increased over the observed period, primarily driven by growth in stockholders’ equity. Debt & leases have also increased, but to a lesser extent. The fluctuation in invested capital in 2023 warrants further investigation to understand the underlying causes.


Cost of Capital

Regeneron Pharmaceuticals Inc., cost of capital calculations

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Long-term debt and finance lease liabilities3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2025-12-31).

1 US$ in thousands

2 Equity. See details »

3 Long-term debt and finance lease liabilities. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Long-term debt and finance lease liabilities3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2024-12-31).

1 US$ in thousands

2 Equity. See details »

3 Long-term debt and finance lease liabilities. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Long-term debt and finance lease liabilities3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2023-12-31).

1 US$ in thousands

2 Equity. See details »

3 Long-term debt and finance lease liabilities. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Long-term debt and finance lease liabilities3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2022-12-31).

1 US$ in thousands

2 Equity. See details »

3 Long-term debt and finance lease liabilities. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Long-term debt and finance lease liabilities3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2021-12-31).

1 US$ in thousands

2 Equity. See details »

3 Long-term debt and finance lease liabilities. See details »

4 Operating lease liability. See details »


Economic Spread Ratio

Regeneron Pharmaceuticals Inc., economic spread ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in thousands)
Economic profit1
Invested capital2
Performance Ratio
Economic spread ratio3
Benchmarks
Economic Spread Ratio, Competitors4
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 Economic profit. See details »

2 Invested capital. See details »

3 2025 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =

4 Click competitor name to see calculations.


The economic spread ratio demonstrates a significant decline from 2021 to 2023, followed by a partial recovery in subsequent years. Economic profit fluctuates over the period, while invested capital consistently increases. This analysis details these trends and their implications.

Economic Spread Ratio
The economic spread ratio decreased substantially from 63.02% in 2021 to 19.28% in 2022, indicating a reduced ability to generate returns exceeding the cost of capital. A further decline to 13.91% occurred in 2023, representing the lowest value within the observed timeframe. The ratio experienced a moderate increase to 17.11% in 2024, but settled at 14.29% in 2025, remaining below the 2021 level. This suggests a weakening, then stabilizing, of the company’s competitive advantage in generating value for investors.
Economic Profit
Economic profit peaked at US$6,797,787 thousand in 2021. A substantial decrease to US$2,368,646 thousand was observed in 2022, followed by a further reduction to US$1,669,000 thousand in 2023. Economic profit then increased to US$2,164,573 thousand in 2024, and decreased slightly to US$1,885,582 thousand in 2025. While fluctuating, the absolute value of economic profit remains positive throughout the period, indicating the company is still generating value, albeit at a decreasing rate initially.
Invested Capital
Invested capital consistently increased throughout the period, rising from US$10,786,500 thousand in 2021 to US$13,198,700 thousand in 2025. This continuous growth in invested capital, coupled with the fluctuations in economic profit, contributes to the observed trends in the economic spread ratio. The increasing capital base suggests ongoing investment in the business, but the ratio indicates that these investments have not consistently translated into proportionally higher returns.

The combination of decreasing economic spread ratio and increasing invested capital suggests that the efficiency of capital allocation may have decreased between 2021 and 2023, before showing some signs of stabilization. Further investigation into the drivers of these trends would be beneficial.


Economic Profit Margin

Regeneron Pharmaceuticals Inc., economic profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in thousands)
Economic profit1
 
Revenues
Add: Increase (decrease) in deferred revenue
Adjusted revenues
Performance Ratio
Economic profit margin2
Benchmarks
Economic Profit Margin, Competitors3
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 Economic profit. See details »

2 2025 Calculation
Economic profit margin = 100 × Economic profit ÷ Adjusted revenues
= 100 × ÷ =

3 Click competitor name to see calculations.


The economic profit margin demonstrates a declining trend over the observed period, followed by a slight stabilization. Economic profit itself fluctuated, while adjusted revenues generally increased. A detailed examination of the economic profit margin reveals key insights into the company’s performance.

Economic Profit Margin Trend
The economic profit margin experienced a substantial decrease from 42.62% in 2021 to 19.41% in 2022. This decline continued into 2023, reaching a low of 12.69%. A modest recovery was noted in 2024, with the margin increasing to 15.00%, but this improvement was not sustained, as the margin decreased slightly to 13.19% in 2025.
Relationship to Economic Profit
The largest decrease in economic profit margin coincided with the largest decrease in economic profit, occurring between 2021 and 2022. While economic profit showed some recovery in 2024, the economic profit margin did not reach its prior high. The economic profit in 2025 decreased from 2024, and the economic profit margin followed suit.
Relationship to Adjusted Revenues
Adjusted revenues decreased from 2021 to 2022, which likely contributed to the decline in economic profit margin. Revenues then increased in both 2023 and 2024, but the economic profit margin did not increase proportionally, suggesting that costs or the capital charge may have risen at a faster rate. Adjusted revenues experienced a slight decrease in 2025, and the economic profit margin also decreased.

Overall, the observed trends suggest that while the company has been able to grow revenues, its ability to translate those revenues into economic profit has been inconsistent. The declining economic profit margin indicates a potential erosion of value creation, despite revenue growth. Further investigation into the factors driving the capital charge and operating costs would be necessary to fully understand the underlying dynamics.